RecruitingPhase 2NCT05570825

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

A Phase 2 Trial of SX-682 and Pembrolizumab in Patients With Treatment Naive Stage IV or Recurrent Non-Small Cell Lung Cancer

Sponsor

University of Washington

Enrollment

30 participants

Start Date

Apr 6, 2023

Study Type

INTERVENTIONAL

Conditions

Metastatic Lung Non-Small Cell Carcinoma Stage IIIC Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Recurrent Lung Non-Small Cell Carcinoma

Summary

This phase II trial tests whether CXCR1/2 inhibitor SX-682 (SX-682) with pembrolizumab works to treat patients with stage IIIC or IV non-small cell lung cancer that has spread to other parts of the body (metastatic) or that has come back (recurrent). SX-682 is a drug that binds to receptors on some types of immune and cancer cells, inhibiting signaling pathways, reducing inflammation, and allowing other types of immune cells to kill and eliminate cancer cells. Pembrolizumab is a monoclonal antibody that binds to a receptor called PD-1 that is found on the surface of T-cells (a type of immune cell), activating an immune response against tumor cells. Giving SX-682 in combination with pembrolizumab may be more effective at treating patients with metastatic or recurrent non-small cell lung cancer than giving these treatments alone.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a drug called SX-682 combined with pembrolizumab (an immunotherapy) for people with advanced or metastatic non-small cell lung cancer (NSCLC). It is looking at whether adding SX-682 helps the immune system fight lung cancer more effectively. **You may be eligible if...** - You are 18 or older - You have confirmed non-small cell lung cancer that has spread or come back, and does not have certain mutations (EGFR, ALK, ROS1, RET) - Your tumor shows PD-L1 expression of at least 1% - You have measurable disease and are in good overall health (ECOG performance status 0 or 1) **You may NOT be eligible if...** - Your tumor has specific gene mutations targeted by other drugs - Your overall health or organ function does not meet study requirements - You have active autoimmune disease requiring systemic treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.